The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
- Citation data:
Expert review of neurotherapeutics, ISSN: 1744-8360, Vol: 17, Issue: 2, Page: 113-121
- Publication Year:
- Repository URL:
- https://touroscholar.touro.edu/tuncom_pubs/122; http://www.tandfonline.com/doi/abs/10.1080/14737175.2016.1271714?journalCode=iern20
- Neuroscience; Medicine; ADHD; Aptensio XR; attention-deficit/hyperactivity disorder; methylphenidate; methylphenidate extended-release; stimulants; Chemicals and Drugs; Medical Sciences
Since Ritalin® (Methylphenidate-Immediate release or MPH-IR) was introduced for the treatment of attention-deficit/hyperactivity disorder, multiple formulations of MPH have been developed. The specific formulation determines the pharmacokinetic (PK) profile and the onset and duration of action for the compound. Areas covered: Aptensio XR® is a multilayer-release MPH (MPH-MLR) consisting of an MPH-IR layer (40%) and an extended-release (ER) portion of 60% of MPH. It has an initial maximum MPH concentration at about two hours (h) and a second concentration peak at approximately 8 h. This formulation allows for a rapid onset of effect by 1 h and a duration of action through 12 h after dosing. The chemistry, PK, efficacy and adverse event profile of MPH-MLR will be reviewed. Expert commentary: Although the PK profile may prove beneficial to patients in the late afternoon and early evening, it is not clear if this is a significant advantage compared with other MPH-ER formulations.